Class I Antiarrhythmic Drugs: Quinidine, Procainamide, Disopyramide, Lidocaine, Mexiletine, Flecainide, and Propafenone

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 911-917

  Gillis, Anne M ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY HEALTH REGION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872774309     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50102-0     Document Type: Chapter

References (40)

1. Stanton MS Class I antiarrhythmic drugs: Quinidine, procainamide, disopyramide, lidocaine, mexiletine, tocainide, phenytoin, moricizine, flecainide, propafenone. Cardiac Electrophysiology: From Cell to Bedside 2000, 890-903. WB Saunders, Philadelphia. 3rd ed. D.P. Zipes, J. Jalife (Eds.).
2. Roden DM Antiarrhythmic drugs. Goodman and Gilmans's The Pharmacological Basis of Therapeutics 2001, 933-970. McGraw-Hill, New York. 10th ed. J.G. Hardman, L.E. Limberg (Eds.).
3. Roden DM Mechanisms and management of proarrhythmia. Am J Cardiol 1998, 82:49I-57I.
4. Gillis AM. Proarrhythmia syndromes. In Electrophysiological Disorders of the Heart. Philadelphia, WB Saunders, in press.
5. Falk RH Atrial fibrillation. N Engl J Med 2001, 344:1067-1078.
6. Grace AA, Camm AJ Quinidine. N Engl J Med 1998, 338:35-45.
7. Grant AO Propafenone: An effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol 1996, 7:353-364.
8. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001, 104:2118-2150.
9. Paul AA, Witchel HJ, Hancox JC Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 2002, 136:717-729.
10. Wang Z, Fermini B, Nattel S Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 1995, 272:184-196.
11. + channel. J Cardiovasc Pharmacol 1998, 32:521-526.
12. Virag L, Varro A, Papp JG Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 1998, 357:268-275.
13. K and its response to quinidine in experimental healed myocardial infarction. J Cardiovasc Electrophysiol 1999, 10:844-854.
14. Gillis AM, Mitchell LB, Wyse DG, et al. Quinidine pharmacodynamics in patients with arrhythmia: Effects of left ventricular function. J Am Coll Cardiol 1995, 25:989-994.
15. Gillis AM, Geonzon TA, Mathison HJ, et al. The effects of barium, dofetilide and 4-aminopyridine on ventricular repolarization in normal and hypertrophied rabbit heart. J Pharmacol Exp Ther 1998, 285:262-270.
16. Zabel M, Hohnloser SH, Behrens S, et al. Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol 1997, 8:1239-1245.
17. Benton RE, Sale M, Flockhart DA, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000, 67:413-418.
18. Thummel KE, Shen DD Design and optimization of dosage regimens: Pharmacokinetic data. Goodman and Gilmans's The Pharmacological Basis of Therapeutics 2001, 1917-2023. McGraw-Hill, New York. 10th ed. J.G. Hardman, L.E. Limberg (Eds.).
19. Wilkinson GR Pharmacokinetics. Goodman and Gilmans's The Pharmacological Basis of Therapeutics 2001, 3-29. McGraw-Hill, New York. 10th ed. J.G. Hardman, L.E. Limberg (Eds.).
20. Thibault B, Nattel S Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: Protagonist. J Cardiovasc Electrophysiol 1999, 10:472-481.
21. Mason JW, Marcus FI, Bigger JT, et al. A summary and assessment of the findings and conclusions of the ESVEM trial. Prog Cardiovasc Dis 1996, 38:347-358.
22. Naccarelli GV, Dorian P, Hohnloser SH, et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996, 77:53A-59A.
23. The AFFIRM First Antiarrhythmic Drug Substudy Investigators Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug administered. J Am Coll Cardiol 2003, 42:20-29.
24. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913-920.
25. Hohnloser SH, van de Loo A, Baedeker F Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995, 26:852-858.
26. Varriale P, Sedighi A, Mirzaietehrane M Ibutilide for termination of atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1999, 22:1267-1269.
27. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996, 78:43-46.
28. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Advanced cardiovascular life support: 7B: Understanding the algorithm approach to ACLS. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000, 102:I140-I141.
29. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000, 101:510-515.
30. Gillis AM, Wyse DG Supraventricular tachycardia. Therapeutic choices 2000, 241-252. Canadian Pharmacists Association, Ottawa, Ontario, Canada. 3rd ed. J.D. Gray (Ed.).
31. Pinter A, Dorian P Intravenous antiarrhythmic agents. Curr Opin Cardiol 2001, 16:17-22.
32. Labbe L, Turgeon J Clinical pharmacokinetics of mexiletine. Clin Pharmacokinet 1999, 37:361-384.
33. Sadowski ZP, Alexander JH, Skrabucha B, et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999, 137:792-798.
34. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995, 92:3381-3386.
35. Shimizu W, Antzelevitch C Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998, 98:2314-2322.
36. Seki A, Hagiwara N, Kasanuki H Effects of propafenone on K currents in human atrial myocytes. Br J Pharmacol 1999, 126:1153-1162.
37. Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, et al. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. Int J Clin Pharmacol Ther 2001, 39:288-292.
38. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000, 102:748-754.
39. Wyse DG, Talajic M, Hafley GE, et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): Drug testing and as-treated analysis. J Am Coll Cardiol 2001, 38:344-351.
40. Priori SG, Napolitano C, Schwartz PJ, et al. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge. Circulation 2000, 102:945-947.